Search results :

Bivalirudin

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: B01AE06

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7
Back pain postmarketing, 2.8% - 43.9% x x x x x x x
Pain 2.4% - 16.6% x x x x x x
Pelvic pain 6.02% - 7.86% x x x x x
Insomnia 1.4% - 6.57% x x x x x x
Anxiety 5.88% - 6.51% x x x x x
Bradycardia postmarketing, 1.2% - 7.62% x x x x x x x
Hypertension 1% - 6.25% x x x x x x
Dyspepsia 4.63% - 5.16% x x x x x
Abdominal pain 0.8% - 4.83% x x x x x x
Nervousness 4.04% - 4.72% x x x x x
Urinary retention 4.12% - 4.56% x x x x x
Ecchymosis postmarketing, 0.0001% - 6% x x
Major bleed postmarketing, 0.001% - 9.25% x x x
Hypotension postmarketing, 0.2% - 17.2% x x x x x x x
Haemorrhage postmarketing, 0.0001% - 28% x x x x
Headache postmarketing, 0.2% - 12.2% x x x x x x x
Body temperature increased 0.5% - 5.02% x x x x x x
Nausea postmarketing, 0.1% - 16.1% x x x x x x x
Injection site pain postmarketing, 0.1% - 12.7% x x x x x x x
Chest pain postmarketing, 2.3% - 3.7% x x x x
Haematoma postmarketing, 0.0001% - 7.5% x x x
Atrial fibrillation 1% - 1.1% x x
Vomiting postmarketing, 0.1% - 7.86% x x x x x x x
Ventricular tachycardia postmarketing, 0.9% - 1% x x
Epistaxis postmarketing, 0.0012% - 1.9% x x x
Angina pectoris postmarketing, 0.2% - 5.3% x x x x x x
Gingival bleeding postmarketing, 0.12% - 1.5% x x
Melaena 0.22% - 0.4% x x
Thrombocytopenia postmarketing, 0.3% - 1.1% x x x x x x
Retroperitoneal haemorrhage postmarketing, 0.069% - 0.697% x x x x x x x
Haemoptysis postmarketing, 0.0046% - 0.5% x x
Haemorrhage intracranial postmarketing, 0.0463% - 1% x x x x x x x
Anaphylactic shock postmarketing x x x x x x
Anaemia postmarketing x x
Arteriovenous fistula postmarketing x
Cardiac tamponade postmarketing x
Compartment syndrome postmarketing x
Connective tissue disorder postmarketing x x
Contusion postmarketing x
Coronary artery thrombosis postmarketing x
Dyspnoea postmarketing x x
Rash postmarketing x x x
Eye disorder postmarketing x
Eye haemorrhage postmarketing x
Gastrointestinal disorder postmarketing x x
Gastrointestinal haemorrhage postmarketing x
Cardiac disorder postmarketing x x
Haematemesis postmarketing x x x
Haematuria postmarketing x x x
Pericardial haemorrhage postmarketing x x
Peritoneal haemorrhage postmarketing x
Hypersensitivity postmarketing x x x x x x
Immune system disorder postmarketing x x
Mediastinal disorder postmarketing x
Myocardial infarction postmarketing x
Nervous system disorder postmarketing x x
Reperfusion injury postmarketing x
Shock postmarketing x x
Thrombosis postmarketing x
Urinary tract disorder postmarketing x
Urticaria postmarketing x x x
Angiopathy postmarketing x x
Pulmonary haemorrhage postmarketing x
Injection site reaction postmarketing x x
Haemoglobin decreased postmarketing x
Unspecified disorder of skin and subcutaneous tissue postmarketing x
Fatal outcomes postmarketing x x x x x x
Oesophageal haemorrhage postmarketing x
Groin pain postmarketing x
Ear haemorrhage postmarketing x
Retroperitoneal haematoma postmarketing x
Anal haemorrhage postmarketing x
Pharyngeal haemorrhage postmarketing x
Blood and lymphatic system disorders postmarketing x
Ear and labyrinth disorders postmarketing x
International normalised ratio increased postmarketing x
Puncture site reaction postmarketing x
Injection site discomfort postmarketing x
Vascular pseudoaneurysm postmarketing x
Coronary stent thrombosis postmarketing x
Vessel puncture site haematoma postmarketing x
Catheter thrombosis postmarketing x
Atelectasis x
Clotting x x x
Infection x x x x
Confusional state x x x x
Facial paralysis x x x x
Oliguria x x x x
Petechiae x
Pleural effusion x
Postoperative hemorrhage x
Pulmonary oedema x x x x
Renal failure x x x x
Syncope x x x x
Ventricular fibrillation x x x x
Injection site haemorrhage x
Vascular anomaly x x x x x
Sepsis x x x x
Increased tendency to bruise x
Frank hematuria x
Electrocardiogram ST segment elevation x
Surgical intervention x x
Drug interaction x
Hemorrhage symptom x
Cerebral ischaemia x x x x
Acute coronary syndrome x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

BIVALIRUDIN / ANGIOMAX

Side effects:30
Source:FDA

BIVALIRUDIN

Side effects:37
Source:FDA Structured Product Label

BIVALIRUDIN

Side effects:37
Source:FDA Structured Product Label

BIVALIRUDIN / ANGIOMAX

Side effects:39
Source:FDA

BIVALIRUDIN / ANGIOMAX

Side effects:42
Source:Health Canada

bivalirudin / bivalirudin

Side effects:73
Source:EMA

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label